
|Videos|June 30, 2017
An Overview of a Study of bb2121 in Multiple Myeloma
Author(s)Sundar Jagannath, MDDS
Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses a first in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma.



















